Clinical Trials Browser

Phase 2/3 × adagrasib × 30 days × Clear all

NCT04613596 2026-05-20

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung